The Food and Drug Administration today approved Biogen’s Aduhelm to treat Alzheimer’s disease, the first new treatment approved for the disease since 2003. The drug was approved using the accelerated approval pathway, which is typically used when a drug for a serious or life-threatening illness is found to have a meaningful therapeutic advantage over existing treatments.

Aduhelm represents a first-of-its-kind treatment approved for Alzheimer’s disease in that it is the first therapy that targets the disease’s fundamental pathophysiology. As part of the accelerated approval provisions, which enables Alzheimer’s patients’ earlier access to treatment, FDA is requiring Biogen to conduct a new randomized, controlled clinical trial to verify the drug’s clinical benefit. In the event the trial fails to verify the drug’s clinical benefit, FDA may withdraw its approval.

Related News Articles

Blog
Recent reports have mischaracterized Medicare’s proposals to account for the impact of COVID-19 in its quality measurement programs as “hiding” important and…
Headline
Inpatient rehabilitation facilities and long-term care hospitals have until April 6 to access updated provider preview reports of their quality data. The…
Headline
The Centers for Medicare & Medicaid Services has extended the deadline for eligible hospitals to submit calendar year 2021 electronic clinical quality…
Chairperson's File
On this episode, I talk with Maureen Bisognano, a prominent authority on improving health care systems. Maureen served as Institute for Healthcare Improvement…
Headline
The Centers for Medicare & Medicaid Services last week granted certain Medicare quality reporting exceptions to acute-care hospitals, ambulatory…
Headline
Commenting today on the Centers for Medicare & Medicaid Services’ home health prospective payment system proposed rule for calendar year 2022, AHA…